Research programme: anti-complement gene therapies - Hemera Biosciences
Latest Information Update: 19 Jul 2016
At a glance
- Originator Hemera Biosciences
- Class Recombinant proteins
- Mechanism of Action Complement system protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dry age-related macular degeneration; Wet age-related macular degeneration